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INTRODUCTION
Gynecological cancer, known to be one of the most
common cancers in women, mainly comprises of
cervical and uterine cancer. Endometrial cancer is the
most common gynecologic malignancy in North America
and Europe, with cervical cancer being the second
most common amongst women worldwide, especially
affecting developing countries.1 No accurate figures
exist for the prevalence and mortality of cancer in
Pakistan, however according to Hanif et al. cervical and
endometrial cancers rank third most frequent
malignancy (5.54%) in female which is consistent with
the Karachi Cancer Registry data by Bhurgri et al.2,3
Surgery is the recommended modality of treatment for
uterine cancer followed by radiotherapy with or without
chemotherapy in adjuvant setting in high risk group of
patients.4,5 For cervical cancer, radiotherapy and
concurrent cisplatin based chemotherapy is the
treatment of choice for FIGO (International Federation of
Gynecology and Obstetrics) stage IB and higher,6,7
surgery is usually reserved for lower stage disease.8
Post-operative pelvic Radiotherapy (RT) is offered in
high risk patients.9
Hence radiation to pelvis is an integral part of the
curative treatment of gynecologic malignancies. Despite
all the precisions and precautions during radiation
therapy, the adjacent healthy tissues do get damaged
resulting in treatment related toxicity that adversely
affects the quality of life; along with being a predictor of
late toxicity.10 Gastrointestinal (GI) and urinary systems
are the most frequently observed systems to be affected
from pelvic radiotherapy while hematologic toxicity is
mainly seen with the addition of chemotherapy.
Literature review on early morbidity of pelvic radio-
therapy along with chemotherapy has revealed high
frequency and severity of varying range. Hematological
toxicity has been reported to range from 20 - 74%
(Grade 1-2:50-70%, Grade 3 - 4 :< 10%), urinary toxicity
as 40 - 74.5% (G1 40%, G2 50.6%) and gastrointestinal
toxicity as 40 - 80% (G1 40 - 50%, G2     40 - 60).10-15
This has resulted in the development and implementation
of different scoring systems for its measurement like
RTOG/EORTC toxicity criteria for radiation therapy
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ABSTRACT
Objective: To determine the frequency and severity of acute toxicity of pelvic radiotherapy for gynecological cancer.
Study Design: A case series.
Place and Duration of Study: Department of Oncology, The Aga Khan University Hospital, Karachi, from March 2011 to
June 2012.
Methodology: A total of 99 patients with histologically proven uterine and cervical cancer, receiving radiation therapy,
were enrolled into the study after informed consent on justification of inclusion and exclusion criteria. Patients were
evaluated for the frequency and severity of pelvic radiotherapy’s side effects according to toxicity criteria based on
RTOG/EORTC and CTC version 2 criteria at the start, during and at the end of treatment. The data was analyzed by using
SPSS version 16.
Results: Out of the 99 enrolled patients, 58 (58.6%) had uterine and 41 (41.4%) had cervical cancer. Mean age was 54.54
±10.29 years. Thirty-five (35.4%) patients received chemotherapy with RT. Mean RT dose was 60.72 ±7.15 Gy. The most
common gastrointestinal adverse effect was diarrhea in 64 (64.6%) followed by proctitis in 55 (55.5%), nausea in 33
(33.3%) and vomiting in 16 (16.2%) patients. Grade (G) 1 was the most frequently observed severity. The most common
hematological toxicity was anemia in 37.8% (n=31/82) {(G1=18 (21.9%), G2=11 (13.4%), G3=2 (2.4%)} followed by
thrombocytopenia in 22.8% (21/92) {(G1=16 (17.3%), G2=2 (2.1%), G3=3 (3.2%)} and neutropenia in 21 (21.2%) {(G1=12
(12.1%), G2=5 (5%), G3=3 (3%), G4=1 (1%)}. Urinary toxicity was observed in 49 (49.5%) patients. On stratification,
chemotherapy and higher RT dose were strong predictor of increased hematological and upper gastrointestinal toxicity
(p < 0.05) and age > 60 years for diarrhea (p < 0.05).
Conclusion: The frequency and severity of acute toxicity of pelvic radiotherapy in women with gynecologic cancers was
found intermediate to high.
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induced adverse effects. Secondly, measurement of
treatment induced adverse effect is a part of several
cancer related clinical trials so that newer cancer
treatment options can be evaluated by its impact on
patients' Quality of Life (QOL) apart from its efficacy.
However, despite its importance there are no local data
available that specifically addresses this issue. Hence,
incidence of acute toxicity of pelvic radiotherapy
treatment in gynecologic cancer patients is unknown in
our population.
The aim of this study was to determine the frequency
and severity of acute toxicity of pelvic radiotherapy for
gynecological cancers in our population so that a
comparison could be made with the West in this regard
which would help us in developing appropriate strategies
for its prevention and better management.
METHODOLOGY
This observational study was carried out at the
Department of Oncology Section of Radiation Oncology,
The Aga Khan University Hospital, Karachi, from March
2011 to June 2012 for a period of 15 months. The
sample size was calculated in an empirical way, based
on frequency and severity of toxicity as mentioned in
recent literature, assuming a power of 80% with 95%
confidence level and bound on error of 10% for sample
estimation. Patients who were referred for radiotherapy
by gynecologist were enrolled into the study on
justification of strict inclusion and exclusion criteria after
informed consent. Non-probability sampling technique
was used.
Inclusion criteria were histologically proven uterine or
cervical cancer and age more than 18 years. Patients
with ovarian, fallopian tube, vaginal and vulvar cancer,
on palliative treatment, previous history of pelvic
radiotherapy, history of inflammatory bowel disease and
fistula were excluded from the study.
All patients received radiation therapy with a minimum
dose of 45 Gray (Gy) in 25 fractions through External
Beam Radiotherapy (EBRT) and a minimum dose of
10Gy in 2 fractions via brachytherapy. Decision
regarding addition of concurrent chemotherapy during
radiation to patients was made by medical oncologist at
the time of referral according to hospital standards.
Patients were assessed before commencement of
radiotherapy, during and at the end of treatment for
frequency and severity of side effects. Gastrointestinal
and urinary toxicities were assessed according to
the Radiation Therapy Oncology Group/European
Organization for Research and Treatment of Cancer
system (RTOG/EORTC), and Common Toxicity Criteria
version 2.0 (CTC version 2.0) was used for hemato-
logical toxicity and recorded in study proforma.16,17
Patients, who had changes in laboratory values or
clinical complaints that might be mistaken for acute side
effects before beginning of radiation, were excluded
from the assessment of one type of toxicity.
All the data were analyzed through Statistical Package
for Social Sciences (SPSS) version 16. All quantitative
variables were presented as mean and standard
deviation while qualitative variables were presented as
frequency and percentages. Chi-square test or Fisher’s
exact test was used to evaluate the statistical difference.
A p-value < 0.05 was considered significant.
RESULTS
A total of 99 patients were recruited in the study, their
demographic characteristics and treatment specifications
are presented in the Table I. Uterine to cervix sub
sites ratio was 1.4. In uterine cancer mean age of
presentation was 56. 25 ±9.07 years, endometroid
adenocarcinoma was the most frequently observed
histology, i.e. 93% (n=54/58) and majority of the patients
had early stage disease, i.e. stage I 55% (32/58). In
cervical cancer mean age of presentation was 52.12
±11.48 years, most frequently observed histology was
squamous cell carcinoma 85% (35/41) and majority 73%
(30/41) had locally advanced stage II and above
disease. Mean radiation therapy dose was 60.7 ±7.15
Gray (Gy). All patients received external beam
radiotherapy (mean dose 46.76 ±2.78 Gy) as well as
brachytherapy (13.94 ±6 Gy). On initial evaluation, 17
patients were found to have hemoglobin level < 11 gm/dl
so they were excluded from anemia analysis, similarly 7
patients were excluded from thrombocytopenia analysis
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Table I: Characteristics of patients (n=99).
Characteristics Number of patients (%)
Age in years , Mean ±S.D (range) 54.54 ±10.24 (24-75)
Sites
Uterus 58 (58.6%)
Cervix 41 (41.4%)
Surgery
Yes 74 (74.7%)
No 25 (25.3%)
FIGO Stage Uterus Cervix
IA 11 (11.1%) 0
IB 21 (21.2%) 11
IIA (11.1%) -
IIB 6 (6.1%) 2 (2%)
IIIA 5 (5%) 16
IIIB (16.2%) -
IIIC 9 (9.1%) 0
IVA 1 (1%) 7
(7.1%) -
5 (5.1%) 0
0 (5.1%) 5
Chemotherapy
Yes 35 (35.4%)
No 64 (64.6%)
Radiotherapy dose in Gray (Gy) 
Mean ±S.D (range)* 60.7 ±7.15 (55-83.4)
*External Beam Radiotherapy +Brachytherapy
as they had platelet counts < 150 x 109/L at the start of
the treatment.
The most frequently observed hematological toxicity
was anemia in 37.8% (n=31/82) followed by thrombo-
cytopenia in 22.8% (21/92) and neutropenia in 21.2%
(21/99). Majority had grade 1 or 2 severity (17 - 34%),
whereas only one patient developed grade 4 neutro-
penia. Diarrhea was the most frequently observed
gastrointestinal toxicity in 64.6% (64/99) followed by
proctitis in 55.5% (55/99). Only grade 1 or 2 gastro-
intestinal toxicity was observed. Almost half of the
patients 49.5% (49/99) developed grade 1 or 2 cystitis
as shown in Table II.
Table III shows the stratification of the outcome with the
patients’ demographic and treatment characteristics.
Chemotherapy was found to have strong association
with the acute hematological and upper gastrointestinal
(GI) toxicities when compared with non-chemotherapy
group. Anemia in 67.7% (n=21/31) vs. 19.6% (10/51),
neutropenia in 51.4% (18/35) vs. 4.6% (3/64), thrombo-
cytopenia in 55.8% (19/34) vs. 3.4% (2/58), nausea in
57.1% (20/35) vs. 20.3% (13/64), vomiting in 31.4%
(11/35) vs. 7.8% (5/64) were observed respectively with
statistical significance of p < 0.001. In locally advanced
disease, anemia was detected in 51% (24/47),
neutropenia in 30.3% (17/56), thrombo-cytopenia in
35.2% (18/51) and vomiting in 25% (14/56). In early
diseases, anemia was observed in 20% (7/35),
neutropenia in 9.3% (4/43), thrombocytopenia in 7.3%
(3/41) and vomiting in 4.6% (2/43) that was statistically
significant (p < 0.05).
A radiation dose of > 60 Gy as compared to < 60 Gy also
showed strong association with hematological toxicities
of anemia in 56.7% (21/37) vs. 22.2% (10/45),
neutropenia in 42.2% (19/45) vs. 3.7% (2/54),
thrombocytopenia in 47.6% (20/42) vs. 2% (1/50), and
vomiting in 24.4% (11/45) vs. 9.2% (5/54) respectively
(p < 0.05). Diarrhea was more frequently observed in
patients of age > 60 years (76.2%, 32/42) as compared
to patients < 60 years (56.1%, 32/57) with statistical
significance (p < 0.03). The proportion of cystitis was
higher in the group of patients with radiation dose of > 60
Gy (60%, 27/45) than patients having radiation dose
< 60 Gy (40.7%, 22/54) with marginal statistical
significance (p=0.056).
DISCUSSION
Radiation doses required for tumor eradication in the
management of uterine and cervical cancer usually
exceed the tolerance of the normal structures that
surround the tumor, leading to toxicity both acute as well
as late that affects patient's quality of life. Therefore,
evaluation of the toxicity has been a part of good clinical
trials. There have been trials that specifically focused on
toxicity as a result of radiotherapy. Vaz et al. reported the
incidence of acute toxicity as high as 93.5% in women
with gynecological cancers who underwent pelvic
radiotherapy.11 In this study, most common acute
reactions (75% - 87%) occurred in the gastrointestinal
system with 23% having grade 1 and 64% grade 2
toxicity.11 This study also showed gastrointestinal
toxicities especially diarrhea (64.6%) and proctitis
(55.5%) as most frequently observed toxicities.
Jereczek-Fossa et al. also reported that gastrointestinal
symptoms were the most common complaints, i.e.
76% in pelvic radiotherapy for endometrial cancer.15
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Table II: Frequency and severity of acute toxicity (n=99).
Toxicity Frequency n (%)
Yes No
Anemia* 31 (37.8)
G1=18 (21.95), G2=11 (13.41), 
G3=2 (2.44) 51 (62.2)
Neutropenia 21 (21.21)
G1=12 (12.12), G2=5 (5.05),  
G3=3 (3.03), G4=1 (1.01) 78 (78.79)
Thrombocytopenia** 21 (22.83)
G1=16 (17.39), G2=2 (2.17), 
G3=3 (3.26) 71 (77.17)
Nausea 33(33.33)
G1=32 (32.32), G2=1 (1.01) 66 (66.67)
Vomiting 16(16.16)
G1=14 (14.14), G2=2 (2.02) 83 (83.84)
Diarrhea 64(64.65)
G1=60(60.61), G2=4 (4.04) 35 (35.35)
Proctitis 55 (55.56)
G1=52 (52.52), G2=3 (3.03) 44 (44.44)
Cystitis 49 (49.49)
G1=45 (45.45), G2=4 (4.04) 50 (50.51)
* 17 patients from anemia and **7 patients from thrombocytopenia were excluded for the
analysis (see text).
Table III: Stratification of toxicities by the patients demographic and treatment characteristics.
Toxicity Sites Chemotherapy Surgery Stage RT dose Age p-value
Uterus Cervix Yes No Yes No Early LAa <60Gy > 60Gy <60 years >60 years p
n=58 n=41 n=35 n=64 n=74 n=25 n=43 n=56 n=54 n=45 n=57 n=42
Anemia** 9 22 21 10 14 17 7 24 10 21 17 14 P=0.4 <0.001
Neutropenia 3 18 18 3 3 18 4 17 2 19 14 7 P=0.4 <0.001
Thrombocytopenia* 1 20 19 2 3 18 3 18 1 20 13 8 P=0.4 <0.001
Nausea 13 20 20 13 17 16 11      22 (p=0.15) 14      19 (p=0.09) 20 13 P=0.67 <0.001
Vomiting 5 11 11 5 8 8 2 14 5 11 11 5 P=0.0 <0.05
Diarrhea 37 27 24 40 44 20 24 40 32 32 32 32 P=0.03 NS ***
Proctitis 32 23 22 33 39 16 21 34 27 28 36 19 NS
Cystitis 27 22 19 30 37 12 22 27 22 27 P=0.0 28 21 NS 
* 7 patients from thrombocytopenia and **17 patients from anemia were excluded for the analysis (see text), *** NS=p >0.05;   a Locally advanced(FIGO stage > II).
Peters et al. found similar results, in patients with
cervical cancer who underwent pelvic radiotherapy,
diarrhea in 55% (G1-2:48%, G3-4:6%), nausea in 29.5%
(G1-2:27.7%, G3:1.8%) and vomiting in 12.5% (G1-2:
10.7%, G3:1.8%).9 However, in this study no grade 3 or
4 toxicity was observed.
The second most common toxicity in this study was
urinary toxicity, i.e. 49.5%, (45.5% grade 1 and 4.04%
grade 2). Jereczek-Fossa et al.15 reported urinary
toxicity to be 41.3% (21% grade 1 and 20% grade 2) that
is consistent with the present finding. However, Vaz et al.
reported higher frequency of urinary toxicity, i.e. 78%
(26.5% grade 1 and 50.6% grade II) however; but
reason for that was not defined.11 Another phase III trial
of pelvic RT after surgery by Keys reported 30% urinary
toxicity (26% G1 and 8% G2).18
Kirwan et al. in a systematic review reported incidence
of hematological toxicity in radiotherapy alone arm,
anemia in 33% (29% grade 1 - 2 and 4% grade 3 - 4),
neutropenia in 47.9% (40% grade 1 - 2 and 7.9% grade
3 - 4) and thrombocytopenia in 10.4% (Grade 1 - 2:10%,
G3-4:0.4%).14 However, the authors here observed
lower hematological toxicity in radiotherapy alone arm,
anemia in 19.6%, neutropenia in 4.6% and thrombo-
cytopenia in 3.4% that might be due to less radiation
dose in the postoperative group to which majority of the
patients belonged.
Introduction of concurrent chemotherapy with radiation
in the management of cervical cancer resulted in
improved disease outcome.6 However, these benefits
are achieved at the expense of increased acute as well
as late toxicity. Roberts et al. reported the interim result
of a phase III trial in which patients with cervical cancer
were randomized to concurrent chemoradiotherapy
versus radiotherapy alone. He found that chemo-
radiotherapy was associated with increased toxicity
leucopenia 44 - 82%, nausea/vomiting from 36.6% to
46.2%, respectively.19 The authors also observed same
finding in this study in which patients, who were treated
with definitive intent, had cervical cancer and in
advanced stage developed more toxicity because of the
use of chemotherapy along with RT in their manage-
ment. However, Farrukh et al. shared experience of
combined modality in cervical cancer management from
single institution. He reported acceptable toxicity
(diarrhea 33%, vomiting 12.5%, cystitis 12.5-29% and
proctitis 8%).20 Moreover, in this study, acute and late
side effects were not separated. A Cochrane review
showed that addition of chemotherapy to RT significantly
increased the rate of grade 1 and 2 hematological,
gastrointestinal and genitourinary toxicity. It resulted in
29% increase in the risk of leucopenia (OR = 1.29, 95%
CI 1.08-1.53, p=0.004) up to a greater than 3-fold
increase in the risk of nausea and vomiting (OR=3.09,
95% CI 2.27-4.21, p < 0.00001).21
Radiotherapy in patients who had abdominopelvic
surgery has increased risk of acute as well as late
toxicity. This might be due to the postoperative
anatomical changes such as increased volume of
intestine in the pelvis, adhesion of the bowel to the
surrounding structures resulting in reduced motility,
therefore, more exposure to radiotherapy. Also
approximation of bowel and urinary bladder to the
radioactive source during brachytherapy increases the
risk. Likewise, typical post-surgery complications like
bladder dysfunctions and infection can confound the
evaluation of post RT bladder toxicity.22 Keys et al.
reported the acute toxicity of pelvic RT after surgery in
endometrial cancer patients. The incidence of
hematological, gastrointestinal and urinary toxicity were
found to be 35.3% (G1-2=35%, G3=0.5%), 68% (G1-
2=63%, G3 and 4=5%) and 30% (G1-2=30%, G3=0%)
respectively as compared to RT alone as 9.9% (G1-
2=9.9%, G3=0.9%), 7% (G1=5%, G2=2%), 7.9%
(G1=4.5%, G2=3.4%) respectively with statistical
significance (p < 0.001).18 However, the authors did not
find surgery to be a predictor of increase acute toxicity in
the present study which is consistent with the finding of
Jereczek-Fossa et al.15
Age is an important predictor of acute RT induced
morbidity although literature appears to be divided
regarding toxicity profile in elderly patients. Various
studies like those of Mitchell et al. and Sakuria et al.
reported an equivalent overall outcome as compared to
younger patients with acceptable toxicity in selected
elderly patients.23 Laurentius et al. found worse
tolerance of CCRT in elderly patients > 60 years
requiring intensive monitoring and treatment protocol
amendment due to severe acute toxicity.24 This study
also showed similar trends of increased toxicity in
women aged > 60 years, however, it was limited to lower
gastrointestinal system (diarrhea and proctitis) only.
Jereczek-Fossa et al. also found that higher radio-
therapy dose and age were important determinant of
acute normal tissue reactions both in univariate as well
as multivariate analysis.15 Whereas, FIGO stage failed
to show any relation. In this study, the authors observed
increased toxicity by increasing the RT dose. Moreover,
as the FIGO stage advances it translates into increased
toxicity which might be due to the increased RT dose
and addition of chemotherapy.
Recent advancement in radiotherapy techniques such
as 3D-conformal radiotherapy, improved immobilization
devices, treatment verification with portal imaging and
IMRT (intensity modulated radiation therapy) show
promising result, in reducing RT induced toxicity.
However, certain investigator have reservation against
IMRT use due to inhomogeneity and higher integral
dose.25
There are certain limitations of this study. Firstly,
accurate comparison of radiotherapy complications from
literature is difficult because of various reporting
methods along with difference in radiotherapy and
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chemotherapy schedules and doses. Secondly, this was
only a single tertiary care center study so the results
may differ from the centers with limited resources.
CONCLUSION
The frequency and severity of acute toxicity of pelvic
radiotherapy in women with gynecological cancer was
found intermediate to high. Gastrointestinal toxicity was
the most frequently observed toxicity followed by urinary
and hematologic toxicity.
Disclosure: It is a dissertation based article.
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